Back to Publications

May 23, 2024 Publications

Nursing home closures sting New England hospitals

Quoted, Modern Healthcare

Jeremy Johnson, Shareholder in our Bankruptcy and Restructuring Group, explains why nursing homes in New England facing bankruptcy are closing instead of undergoing restructuring.

Resources

Read the full article

Firm Highlights

Slide 1 of 6

Publication
2027 OPPS Proposed Rule: Mandatory Provider-Based Attestations Signal a New Compliance Era
Last week, the Centers for Medicare & Medicaid Services (CMS) published proposed rules mandating the submission of provider-based attestations for off-campus hospital outpatient departments as part of the 2027 Outpatient Prospective Payment System (OPPS) Proposed Rule (Proposed Rule).
Read more
Publication
Federal Circuit Finds Method-of-Treatment Claims Including In Vivo Dosing Limitations Are Not Enabled By In Vitro Data
In Wyeth LLC v. AstraZeneca Pharmaceuticals LP, the Federal Circuit affirmed judgment as a matter of law that Wyeth's method-of-treatment claims were invalid for lack of enablement, wiping out a $107.5 million jury verdict over AstraZeneca's Tagrisso®.
Read more
Event
When Websites Become Litigation Targets | Digital Risk and Innovation Summit Series
Websites can be valuable business assets, but their public availability makes them easy targets for litigation.
Read more
Event
Doctor, Doctor, Give Me the News | Hot Town, Summer in the City: What the Washington is Going On?! - Webinar Series
Join Polsinelli's public policy team for a three-part lunch and learn series to hear what they’re watching in federal oversight and health care policy this season.
Read more
Blog
New York State is Set to Impose New Requirements for Separation Agreements
Read more
News
Polsinelli Adds Timothy Ayotte in Boston, Strengthening Life Sciences Corporate & Transactional Capabilities
Polsinelli is pleased to announce that Timothy Ayotte has joined the firm as a shareholder in its Boston office, strengthening the firm’s corporate and transactional depth for life sciences, biotechnology and health care companies.
Read more